AOK RHEINLANDPFALZSAARLAND DIE GESUNDHEITSKASSE
A United Kingdom buyer, with 13 published contracts, worth £335k, most recently 4 months ago.
Top 2 suppliers won 100% of awarded value — £306k of £306k across 2 awards.
This contract opportunity involves the establishment of non-exclusive discount contracts for the medications Olmesartan and Hydrochlorothiazide. These contracts will be in effect from February 1, 2026, to January 31, 2028, and can be signed at any time during this period (open-house model). Please n
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical Alfacalcidol, in accordance with specific regulations, for the period from February 1, 2026, to January 31, 2028. Suppliers can enter into contracts at any time during this period, followi
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Glatiramer Acetate, specifically for pre-filled syringes. The contracts will be in effect from February 1, 2026, to January 31, 2028, with the option for suppliers to enter into contracts at a
This contract opportunity involves the establishment of non-exclusive discount contracts for medicines containing the active ingredient Bexarotene, in accordance with German social law. The contracts will be valid from December 1, 2025, to November 30, 2027, and can be signed at any time during this
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Tramadol and Paracetamol, in accordance with German social law. The contracts will be valid from October 1, 2025, to September 30, 2027, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for medications containing the active ingredients Olodaterol and Tiotropium Bromide. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the possibility of entering into contracts a
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Denosumab, marketed as Xgeva, in accordance with German social law. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into agreements at any
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical product Somatropin, classified under ATC code H01AC01. The contracts will be valid from July 1, 2025, to June 30, 2027, and suppliers can enter into contracts at any time during this perio
